|
1. Rugg SS, Bailey AL, Browning SR. Preventing
cardiovascular disease in Kentucky:
epidemiology, trends, and strategies for the
future. J Ky Med Assoc. 2008 Apr;106(4):149-61.
2. Johnson RJ, Segal MS, Sautin Y, et al.
Potential role of sugar (fructose) in the
epidemic of hypertension, obesity and the
metabolic syndrome, diabetes, kidney disease,
and cardiovascular disease. Am J Clin Nutr. 2007
Oct;86(4):899-906.
3. Forshee RA, Storey ML, Allison DB, et al.
A critical examination of the evidence relating
high fructose corn syrup and weight gain. Crit
Rev Food Sci Nutr. 2007;47(6):561-82.
4. Ouyang X, Cirillo P, Sautin Y, et al.
Fructose consumption as a risk factor for
non-alcoholic fatty liver disease. J Hepatol.
2008 Jun;48(6):993-9.
5. Miller A, Adeli K. Dietary fructose and
the metabolic syndrome. Curr Opin Gastroenterol.
2008 Mar;24(2):204-9.
6. Rutledge AC, Adeli K. Fructose and the
metabolic syndrome: pathophysiology and
molecular mechanisms. Nutr Rev. 2007 Jun;65(6 Pt
2):S13-23.
7. Gaby AR. Adverse effects of dietary
fructose. Altern Med Rev. 2005
Dec;10(4):294-306.
8. Nakagawa T, Tuttle KR, Short RA, Johnson
RJ. Hypothesis: fructose-induced hyperuricemia
as a causal mechanism for the epidemic of the
metabolic syndrome. Nat Clin Pract Nephrol. 2005
Dec;1(2):80-6.
9. Basciano H, Federico L, Adeli K. Fructose,
insulin resistance, and metabolic dyslipidemia.
Nutr Metab (Lond). 2005 Feb 21;2(1):5.
10. Rayssiguier Y, Gueux E, Nowacki W, Rock
E, Mazur A. High fructose consumption combined
with low dietary magnesium intake may increase
the incidence of the metabolic syndrome by
inducing inflammation. Magnes Res. 2006
Dec;19(4):237-43.
11. Segal MS, Gollub E, Johnson RJ. Is the
fructose index more relevant with regards to
cardiovascular disease than the glycemic index?
Eur J Nutr. 2007 Oct;46(7):406-17.
12. Elliott SS, Keim NL, Stern JS, Teff K,
Havel PJ. Fructose, weight gain, and the insulin
resistance syndrome. Am J Clin Nutr. 2002
Nov;76(5):911-22.
13. Taylor EN, Curhan GC. Fructose
consumption and the risk of kidney stones.
Kidney Int. 2008 Jan;73(2):207-12.
14. Johnson RJ, Sautin YY, Oliver WJ, et al.
Lessons from comparative physiology: could uric
acid represent a physiologic alarm signal gone
awry in western society? J Comp Physiol [B].
2008 Jul 23.
15. Choi JW, Ford ES, Gao X, Choi HK.
Sugar-sweetened soft drinks, diet soft drinks,
and serum uric acid level: the Third National
Health and Nutrition Examination Survey.
Arthritis Rheum. 2008 Jan 15;59(1):109-16.
16. Hak AE, Choi HK. Lifestyle and gout. Curr
Opin Rheumatol. 2008 Mar;20(2):179-86.
17. Choi HK, Curhan G. Soft drinks, fructose
consumption, and the risk of gout in men:
prospective cohort study. BMJ. 2008 Feb
9;336(7639):309-12.
18. Thuy S, Ladurner R, Volynets V, et al.
Nonalcoholic fatty liver disease in humans is
associated with increased plasma endotoxin and
plasminogen activator inhibitor 1 concentrations
and with fructose intake. J Nutr. 2008
Aug;138(8):1452-5.
19. Preiss D, Sattar N. Non-alcoholic fatty
liver disease: an overview of prevalence,
diagnosis, pathogenesis and treatment
considerations. Clin Sci (Lond). 2008
Sep;115(5):141-50.
20. Bray GA, Nielsen SJ, Popkin BM.
Consumption of high-fructose corn syrup in
beverages may play a role in the epidemic of
obesity. Am J Clin Nutr. 2004 Apr;79(4):537-43.
21. Vos MB, Kimmons JE, Gillespie C, Welsh J,
Blanck HM. Dietary fructose consumption among US
children and adults: the Third National Health
and Nutrition Examination Survey. Medscape J
Med. 2008 Jul 9;10(7):160.
22. Gross LS, Li L, Ford ES, Liu S. Increased
consumption of refined carbohydrates and the
epidemic of type 2 diabetes in the United
States: an ecologic assessment. Am J Clin Nutr.
2004 May;79(5):774-9.
23. Beck-Nielsen H, Pedersen O, Lindskov HO.
Impaired cellular insulin binding and insulin
sensitivity induced by high-fructose feeding in
normal subjects. Am J Clin Nutr. 1980
Feb;33(2):273-8.
24. Hallfrisch J, Ellwood KC, Michaelis OE
4th, Reiser S, O’Dorisio TM, Prather ES. Effects
of dietary fructose on plasma glucose and
hormone responses in normal and hyperinsulinemic
men. J Nutr. 1983 Sep;113(9):1819-26.
25. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng
WT, Chu CH. Functional interaction of AT1 and
AT2 receptors in fructose-induced insulin
resistance and hypertension in rats. Metabolism.
2005 Feb;54(2):157-64.
26. Plante GE, Perreault M, Lanthier A,
Marette A, Maheux P. Reduction of endothelial
NOS and bradykinin-induced extravasation of
macromolecules in skeletal muscle of the
fructose-fed rat model. Cardiovasc Res. 2003 Oct
1;59(4):963-70.
27. Avramoglu RK, Qiu W, Adeli K. Mechanisms
of metabolic dyslipidemia in insulin resistant
states: deregulation of hepatic and intestinal
lipoprotein secretion. Front Biosci. 2003 Jan
1;8:d464-76.
28. Thirunavukkarasu V, Anitha Nandhini AT,
Anuradha CV. Effect of alpha-lipoic acid on
lipid profile in rats fed a high-fructose diet.
Exp Diabesity Res. 2004 Jul-Sep;5(3):195-200.
29. Tokita Y, Hirayama Y, Sekikawa A, et al.
Fructose ingestion enhances atherosclerosis and
deposition of advanced glycated end-products in
cholesterol-fed rabbits. J Atheroscler Thromb.
2005;12(5):260-7.
30. Ong JP, Pitts A, Younossi ZM. Increased
overall mortality and liver-related mortality in
non-alcoholic fatty liver disease. J Hepatol.
2008 Oct;49(4):608-12.
31. Smedile A, Bugianesi E. Steatosis and
hepatocellular carcinoma risk. Eur Rev Med
Pharmacol Sci. 2005 Sep-Oct;9(5):291-3.
32. Dunn W, Xu R, Wingard DL, et al.
Suspected Nonalcoholic Fatty Liver Disease and
Mortality Risk in a Population-Based Cohort
Study. Am J Gastroenterol. 2008 Aug 5.
33. Raszeja-Wyszomirska J, Lawniczak M,
Marlicz W, Miezynska-Kurtycz J, Milkiewicz P.
Non-alcoholic fatty liver disease—new view. Pol
Merkur Lekarski. 2008 Jun;24(144):568-71.
34. Dhar A, Desai K, Kazachmov M, Yu P, Wu L.
Methylglyoxal production in vascular smooth
muscle cells from different metabolic
precursors. Metabolism. 2008 Sep;57(9):1211-20.
35. Wang X, Jia X, Chang T, Desai K, Wu L.
Attenuation of hypertension development by
scavenging methylglyoxal in fructose-treated
rats. J Hypertens. 2008 Apr;26(4):765-72.
36. Mikulikova K, Eckhardt A, Kunes J, Zicha
J, Miksik I. Advanced glycation end-product
pentosidine accumulates in various tissues of
rats with high fructose intake. Physiol Res.
2008;57(1):89-94.
37. Li SY, Ren J. Assessment of protein
glycoxidation in ventricular tissues. Methods
Mol Med. 2007;139:313-28.
38. McPherson JD, Shilton BH, Walton DJ. Role
of fructose in glycation and cross-linking of
proteins. Biochemistry. 1988 Mar
22;27(6):1901-7.
39. Peppa M, Uribarri J, Vlassara H. Aging
and glycoxidant stress. Hormones (Athens). 2008
Apr;7(2):123-32.
40. Gasser A, Forbes JM. Advanced glycation:
implications in tissue damage and disease.
Protein Pept Lett. 2008;15(4):385-91.
41. Grillo MA, Colombatto S. Advanced
glycation end-products (AGEs): involvement in
aging and in neurodegenerative diseases. Amino
Acids. 2008 Jun;35(1):29-36.
42. Levi B, Werman MJ. Long-term fructose
consumption accelerates glycation and several
age-related variables in male rats. J Nutr. 1998
Sep;128(9):1442-9.
43. Stirban A, Negrean M, Gotting C, et al.
Dietary advanced glycation endproducts and
oxidative stress: in vivo effects on endothelial
function and adipokines. Ann NY Acad Sci. 2008
Apr;1126:276-9.
44. Versari D, Daghini E, Virdis A, Ghiadoni
L, Taddei S. The aging endo-thelium,
cardiovascular risk and disease. Exp Physiol.
2008 Sep 19.
45. Smit AJ, Hartog JW, Voors AA, van
Veldhuisen DJ. Advanced glycation endproducts in
chronic heart failure. Ann N Y Acad Sci. 2008
Apr;1126:225-30.
46. Gao X, Qi L, Qiao N, et al. Intake of
added sugar and sugar-sweetened drink and serum
uric acid concentration in US men and women.
Hypertension. 2007 Aug;50(2):306-12.
47. Heinig M, Johnson RJ. Role of uric acid
in hypertension, renal disease, and metabolic
syndrome. Cleve Clin J Med. 2006
Dec;73(12):1059-64.
48. Nakagawa T, Hu H, Zharikov S, et al. A
causal role for uric acid in fructose-induced
metabolic syndrome. Am J Physiol Renal Physiol.
2006 Mar;290(3):F625-31.
49. Akhavan T, Anderson GH. Effects of
glucose-to-fructose ratios in solutions on
subjective satiety, food intake, and satiety
hormones in young men. Am J Clin Nutr. 2007
Nov;86(5):1354-63.
50. Ahmed N, Thornalley PJ. Advanced
glycation endproducts: what is their relevance
to diabetic complications? Diabetes Obes Metab.
2007 May;9(3):233-45.
51. Anon. Benfotiamine. Monograph. Altern Med
Rev. 2006 Sep;11(3):238-42.
52. Du X, Edelstein D, Brownlee M. Oral
benfotiamine plus alpha-lipoic acid normalises
complication-causing pathways in type 1
diabetes. Diabetologia. 2008 Oct;51(10):1930-2.
53. Stirban A, Negrean M, Stratmann B, et al.
Benfotiamine prevents macro- and microvascular
endothelial dysfunction and oxidative stress
following a meal rich in advanced glycation end
products in individuals with type 2 diabetes.
Diabetes Care. 2006 Sep;29(9):2064-71.
54. Schmid U, Stopper H, Heidland A, Schupp
N. Benfotiamine exhibits direct antioxidative
capacity and prevents induction of DNA damage in
vitro. Diabetes Metab Res Rev. 2008
Jul;24(5):371-7.
55. Thirunavukkarasu V, Anitha Nandhini AT,
Anuradha CV. Lipoic acid improves glucose
utilisation and prevents protein glycation and
AGE formation. Pharmazie. 2005 Oct;60(10):772-5.
56. Vincent AM, Perrone L, Sullivan KA, et
al. Receptor for advanced glycation end products
activation injures primary sensory neurons via
oxidative stress. Endocrinology. 2007
Feb;148(2):548-58.
57. Hao J, Shen W, Tian C, et al.
Mitochondrial nutrients improve immune
dysfunction in the type 2 diabetic Goto-Kakizaki
rats. J Cell Mol Med. 2008 Apr 9.
58. Sena CM, Nunes E, Louro T, et al. Effects
of alpha-lipoic acid on endothelial function in
aged diabetic and high-fat fed rats. Br J
Pharmacol. 2008 Mar;153(5):894-906.
59. Foster TS. Efficacy and safety of alpha-lipoic
acid supplementation in the treatment of
symptomatic diabetic neuropathy. Diabetes Educ.
2007 Jan;33(1):111-7.
60. Aliev G, Liu J, Shenk JC, et al. Neuronal
mitochondrial amelioration by feeding acetyl-L-carnitine
and lipoic acid to aged rats. J Cell Mol Med.
2008 Mar 28.
61. Palaniappan AR, Dai A. Mitochondrial
ageing and the beneficial role of alpha-lipoic
acid. Neurochem Res. 2007 Sep;32(9):1552-8.
62. Wang AM, Ma C, Xie ZH, Shen F. Use of
carnosine as a natural anti-senescence drug for
human beings. Biochemistry (Mosc). 2000
Jul;65(7):869-71.
63. Hipkiss AR, Preston JE, Himsworth DT, et
al. Pluripotent protective effects of carnosine,
a naturally occurring dipeptide. Ann NY Acad
Sci. 1998 Nov 20;854:37-53.
64. Hipkiss AR. Would carnosine or a
carnivorous diet help suppress aging and
associated pathologies? Ann NY Acad Sci. 2006
May;1067:369-74.
65. Reddy VP, Garrett MR, Perry G, Smith MA.
Carnosine: a versatile antioxidant and
antiglycating agent. Sci Aging Knowledge
Environ. 2005 May 4;2005(18):pe12.
66. Rashid I, van Reyk DM, Davies MJ.
Carnosine and its constituents inhibit glycation
of low-density lipoproteins that promotes foam
cell formation in vitro. FEBS Lett. 2007 Mar
6;581(5):1067-70.
67. Williams ME, Bolton WK, Khalifah RG, et
al. Effects of pyridoxamine in combined phase 2
studies of patients with type 1 and type 2
diabetes and overt nephropathy. Am J Nephrol.
2007;27(6):605-14.
68. Williams ME. New potential agents in
treating diabetic kidney disease: the fourth
act. Drugs. 2006;66(18):2287-98.
69. Davidson MH, Yannicelli HD. New concepts
in dyslipidemia in the metabolic syndrome and
diabetes. Metab Syndr Relat Disord.
2006;4(4):299-314.
70. Robinson LE, Buchholz AC, Mazurak VC.
Inflammation, obesity, and fatty acid
metabolism: influence of n-3 polyunsaturated
fatty acids on factors contributing to metabolic
syndrome. Appl Physiol Nutr Metab. 2007
Dec;32(6):1008-24.
71. Carpentier YA, Portois L, Malaisse WJ.
n-3 fatty acids and the metabolic syndrome. Am J
Clin Nutr. 2006 Jun;83(6 Suppl):1499S-504S.
72. Lombardo YB, Hein G, Chicco A. Metabolic
syndrome: effects of n-3 PUFAs on a model of
dyslipidemia, insulin resistance and adiposity.
Lipids. 2007 May;42(5):427-37.
73. Nettleton JA, Katz R. n-3 long-chain
polyunsaturated fatty acids in type 2 diabetes:
a review. J Am Diet Assoc. 2005
Mar;105(3):428-40.
74. Pershadsingh HA. Alpha-lipoic acid:
physiologic mechanisms and indications for the
treatment of metabolic syndrome. Expert Opin
Investig Drugs. 2007 Mar;16(3):291-302.
75. McMackin CJ, Widlansky ME, Hamburg NM, et
al. Effect of combined treatment with alpha-Lipoic
acid and acetyl-L-carnitine on vascular function
and blood pressure in patients with coronary
artery disease. J Clin Hypertens (Greenwich).
2007 Apr;9(4):249-55.
76. Gao X, Curhan G, Forman JP, Ascherio A,
Choi HK. Vitamin C Intake and Serum Uric Acid
Concentration in Men. J Rheumatol. 2008
Sep;35(9):1853-8. |